title: Thermoradiotherapy combined with p53 gene therapy of human salivary gland adenocarcinoma cell line.
abstract: We report on thermoradiotherapy combined with p53 gene therapy in the human salivary gland adenocarcinoma cell line HSG. HSG cells were successfully infected at a rate of 62.3% with MOIs of 20 of either AxCAip53 or AxCAiLacZ. The AxCAiLacZ did not inhibit the survival of the HSG cells. The survival fractions of AxCAip53-infected HSG cells were lower than those of the AxCAiLacZ-infected HSG cells, but there was no significant difference (p=0.30). AxCAip53 decreased the survival rates of thermotherapy (43 degrees C; p=0.084 and 44 degrees C; p=0.18), radiotherapy (6 Gy; p=0.20) and thermoradiotherapy (6 Gy plus 43 degrees C; p=0.24 and 6 Gy plus 44 degrees C; p=0.96), but there were no significant differences. In comparing the survival rates of thermoradiotherapy with those of thermotherapy and radiotherapy, thermoradiotherapy, regardless of the combination with p53 gene therapy, demonstrated actual survival rates lower than theoretical survival rates based on survival rates of thermotherapy multiplied by survival rates of radiotherapy. This result indicates that thermoradiotherapy is effective in the treatment of HSG cells. Thermoradiotherapy combined with p53 gene therapy was the most effective therapy among the combinations of therapies demonstrating that thermoradiotherapy combined with p53 gene therapy may be a useful tool in the treatment of HSG cells.
authors.affiliation: Department of Oral and Maxillofacial Radiology, Field of Tumor Biology, Graduate School of Medicine and Dentistry, Okayama University, Japan. asaumi@md.okayama-u.ac.jp
authors.forename: Jun-Ichi
authors.initials: J
authors.lastname: Asaumi
authors.forename: Yuzuru
authors.initials: Y
authors.lastname: Higuchi
authors.forename: Jun
authors.initials: J
authors.lastname: Murakami
authors.forename: Hidenobu
authors.initials: H
authors.lastname: Matsuzaki
authors.forename: Toru
authors.initials: T
authors.lastname: Wakasa
authors.forename: Tetsuyoshi
authors.initials: T
authors.lastname: Inoue
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shigehara
authors.forename: Hironobu
authors.initials: H
authors.lastname: Konouchi
authors.forename: Miki
authors.initials: M
authors.lastname: Hisatomi
authors.forename: Shoji
authors.initials: S
authors.lastname: Kawasaki
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kuroda
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Hiraki
authors.forename: Kanji
authors.initials: K
authors.lastname: Kishi
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy*; D000256:Adenoviridae / Q000235:genetics; D002470:Cell Survival; D003131:Combined Modality Therapy; D004307:Dose-Response Relationship, Radiation; D016158:Genes, p53; D015316:Genetic Therapy; D006801:Humans; D006979:Hyperthermia, Induced; D011836:Radiation Tolerance; D012468:Salivary Gland Neoplasms / Q000628:therapy*; D013696:Temperature; D013997:Time Factors; D014162:Transfection; D014407:Tumor Cells, Cultured; D001616:beta-Galactosidase / Q000378:metabolism
chemical_list: D001616:beta-Galactosidase